Please login to the form below

Not currently logged in
Email:
Password:

Dr Alan Joslyn becomes president and CEO of Oragenics

He will also serve on the company’s board of directors

Florida-based Oragenics has appointed Dr Alan Joslyn as its new president, chief executive officer and member of the board of directors.

Dr Joslyn was a founding partner of Lazarus Pharmaceuticals, and has served as chief executive officer at both Edusa Pharmaceuticals and Sentinella Pharmaceuticals.

Prior to this, he worked at Penwest Pharmaceuticals as the senior vice president of research and development, and has held senior drug development positions within Johnson & Johnson.

Dr Frederick Telling, chairman of Oragenics, said: “As Oragenics opens this new chapter, the board and I are confident that Dr Joslyn is the right person to lead the company forward.

“He has proven ability to create strategic clarity, drive innovation and ensure disciplined execution as well as a depth of experience from serving a large pharmaceutical company and smaller research oriented companies, with particular experience in gastrointestinal disease and lantibiotics.

“We believe that his passion for technology will help ensure that Oragenics continues to strive to deliver innovations that have a positive impact on people's lives.”

17th June 2016

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Weber Shandwick

At Weber Shandwick, engagement has always been the cornerstone of health communications.We make health matter. Health is a basic human...

Latest intelligence

eyeforpharma Marketing and Customer Innovation Europe
By Richard Springham...
US Drug pricing
The Golden Goose
Why it’s so hard for the US to curb runaway drug prices...
What is changing in cardiovascular disease care?
Paul Midgley, of Wilmington Healthcare, explores the NHS Long-term Plan’s strategy for tackling cardiovascular disease and what it means for pharma...

Infographics